NCI Division of Cancer Biology’s Post

Our review on Peptides as innovative strategies to combat drug resistance in cancer therapy has been published in Drug Discovery today and is now available for reading. The review's three areas of focus for peptides to target drug resistant-cancer: Targeting tumour lipid membranes to kill proliferative & non-proliferative cells Peptide-drug conjugates to overcome drug efflux & improve tumour selectivity Cyclic peptides for targeting intracellular proteins in drug-resistant cancer Many thanks to my two amazing supervisors Sónia Troeira Henriques Henriques & Aurelie Benfield for their help and input along the way. Hopefully the beginning of more to come. Translational Research Institute Australia QUT (Queensland University of Technology)

(Celecoxib + tucidinostat) by Great Novel Therapeutics Biotech & Medicals for Metastatic Colorectal Cancer. (Celecoxib + tucidinostat) is under clinical development by Great Novel Therapeutics Biotech & Medicals and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData, Phase I drugs for Metastatic Colorectal Cancer have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData Plc 's report assesses how (Celecoxib + tucidinostat)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare... Check out the full story 👉 https://zurl.co/wV3s (PHARMAC) #biotech #genetics

The Advantages of Using Primary Derived Cancer Cell Lines in Drug Discovery IN THE RAPIDLY EVOLVING FIELD OF DRUG DISCOVERY, CHOOSING THE RIGHT CELL MODEL IS CRUCIAL FOR DEVELOPING EFFECTIVE CANCER TREATMENTS. TRADITIONALLY, ESTABLISHED CANCER CELL LINES HAVE BEEN WIDELY USED DUE TO THEIR EASE OF CULTURE AND AVAILABILITY. Enhanced Relevance: They better mimic the tumor's original characteristics, providing more accurate insights. Improved Predictability: These cell lines reflect patient-specific responses, leading to more reliable drug efficacy predictions. Diverse Genetic Profiles: They capture the genetic diversity of cancer, aiding in the development of targeted therapies. https://lnkd.in/g7MczWS5 #DrugDiscovery #CancerResearch #PrimaryCancerCellLines #InnovativeTherapies #ResearchAdvancements #Biotech #CancerTreatment

Read the Editorial Commentary on MET targeted therapy in non-small cell lung cancer patients with MET exon 14-skipping mutations by Edyta Maria Urbanska, Jens Mollerup, and Jan Trøst Jørgensen and recently published in Translational Lung Cancer Research (Open Access): https://lnkd.in/dM5F5KvZ #medicine #pharmaceuticals #oncology #precisionmedicine #biomarkers

Advancing a first-in-class AI-enabled cancer drug. A new article from Diana Spencer in Drug Discovery World looks at our REC-1245 program, a potentially first-in-class small molecule that recently received FDA IND clearance for a Phase 1/2 clinical trial for biomarker-enriched solid tumors and lymphoma. ▪ She writes: “Recursion identified the novel regulatory role of RBM39 associated with CDK12 using its maps of biology and first reported this relationship in early 2023, and notes that “preclinical data support that RBM39 degradation induces splicing defects which downregulate DNA Damage Response (DDR) networks and cell cycle checkpoints.” ▪ Chris Gibson says: “REC-1245 is a prime example of using an expansive AI-enabled platform for drug discovery. After exploring many predicted biological and chemical relationships across our maps of biology, we identified RMB39 as a novel target that looks functionally similar to the well-known but hard to drug target CDK12. We also identified and optimized small molecules that target RBM39 without directly impacting CDK12 or CDK13 using these same AI-enabled maps.” 👉 Read more: https://lnkd.in/ePy9XY5S #ai #clinicaltrials #techbio #cancer #tumor #cdk12 #rbm39

Our paper got another highlight, thanks! We are at the dawn of a whole new era of insights into cancer treatments and outcome management using applied math and new computational tools. Moffitt Oncology Network GYNCA GYN Cancers Alliance

Addressing cancer drug resistance demands precise tools to uncover resistance mechanisms and drive therapeutic innovation. We offer a diverse array of models—cell line-derived xenografts (CDX), patient-derived xenografts (PDX), and pretreated models—that allows researchers like you to characterize resistance phenotypes and refine therapeutic strategies for improved clinical outcomes. To see how these models can transform your research, make use of our free resources below. 📄Blog Post: Combating Cancer Drug Resistance with In Vivo Models ➡️https://hubs.la/Q02YdGKC0 📄Application Note: HCC827 NSCLC Cell Line Derived Xenograft Model ➡️https://hubs.la/Q02YdNTG0 📄White Paper: Pretreated Patient-derived Xenograft Models: A Key Tool for Developing Innovative Anticancer Therapies ➡️https://hubs.la/Q02YdBMS0

Poly (ADP-ribose) polymerase (PARP) protein family members are potential therapeutic targets for a number of cancers including breast, lung, prostate, and pancreatic cancers. When identifying and developing drugs such as PARP inhibitors or PARP-degrading proteolysis targeting chimeras (PROTACs), researchers need to test for PARP enzymatic activity using in vitro tests. With various assays to choose from, scientists must understand their options to optimize therapeutic development. Download this ebook from BPS Bioscience Inc. to learn about developing cancer therapeutics against the PARP family. #AD https://ow.ly/7uQU50QI1MU

Colorectal Cancer Screening Enhanced: FDA Approves ColoSense mt-sRNA Test for Early Detection The FDA has approved ColoSense, a multitarget stool RNA test, for colorectal cancer screening in adults aged 45 or older who are at average risk. The test detects colorectal neoplasia-associated RNA markers and occult hemoglobin in stool, and a positive result may indicate the presence of colorectal cancer, advanced adenomas, or precancerous lesions. The approval was based on the outcomes of the CRC-PREVENT trial, which showed that ColoSense accurately identifies colorectal abnormalities. The test offers a reliable and convenient option for screening, potentially leading to earlier detection and improved patient outcomes. ColoSense is expected to be launched in the United States later this year or in early 2025. For more details please click the link! https://lnkd.in/dvRdWuAC #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical

#TNBC #MLK3_PROTAC #CEP1347_VHL_02 This recently published approach (https://lnkd.in/gCcBGy9N) highlights the potential of targeted protein degradation (TDP) in developing more effective treatments for cancers with limited therapeutic options. The development of CEP1347-VHL-02 as a selective MLK3 degrader represents a significant advancement in the treatment of triple-negative breast cancer (TNBC). By leveraging PROTAC technology, this compound specifically targets MLK3 for degradation via the ubiquitin-proteasome system, without affecting other MLK family members. In preclinical models, CEP1347-VHL-02 has demonstrated promising results, including the reduction of clonogenic and migratory potential, induction of cell cycle arrest, and apoptosis in TNBC cells. These findings suggest that CEP1347-VHL-02 could be a valuable therapeutic strategy for targeting MLK3 in TNBC, potentially improving outcomes for patients with this aggressive cancer subtype.